Prime Medicine (PRME) Equity Ratio: 2021-2025
Historic Equity Ratio for Prime Medicine (PRME) over the last 3 years, with Sep 2025 value amounting to 0.42.
- Prime Medicine's Equity Ratio fell 26.19% to 0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42, marking a year-over-year decrease of 26.19%. This contributed to the annual value of 0.51 for FY2024, which is 25.01% down from last year.
- Per Prime Medicine's latest filing, its Equity Ratio stood at 0.42 for Q3 2025, which was up 92.68% from 0.22 recorded in Q2 2025.
- Over the past 5 years, Prime Medicine's Equity Ratio peaked at 0.88 during Q1 2023, and registered a low of -1.04 during Q3 2022.
- For the 3-year period, Prime Medicine's Equity Ratio averaged around 0.62, with its median value being 0.69 (2023).
- Its Equity Ratio has fluctuated over the past 5 years, first spiked by 269.58% in 2022, then slumped by 71.18% in 2025.
- Quarterly analysis of 5 years shows Prime Medicine's Equity Ratio stood at -0.52 in 2021, then spiked by 269.58% to 0.88 in 2022, then decreased by 21.79% to 0.69 in 2023, then declined by 25.01% to 0.51 in 2024, then fell by 26.19% to 0.42 in 2025.
- Its Equity Ratio stands at 0.42 for Q3 2025, versus 0.22 for Q2 2025 and 0.33 for Q1 2025.